

Under the Auspices of




**AMERICAN SOCIETY OF
HYPERTENSION**



**ASIAN SOCIETY OF CONTINUING
MEDICAL EDUCATION**

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



**October 11th-12th, 2014,
Ramoji Film City, Hyderabad, India**

FACULTY

- ▲ Eric Peterson, MD.
Duke University, Durham, USA
- ▲ Sanjay Rajagopalan, MD
University of Maryland, Baltimore, USA
- ▲ Allan Sniderman, MD, FRCP.
McGill University, Montreal, Canada
- ▲ G. Vijayaraghavan, MD, DM, FRCP(Edin)
D.Sc.,FRCP(Lond.), FAHA
Kerala Institute of Medical Sciences
Trivandrum, India
- ▲ Atul Ingale, MD, MRCP,
Fellow American Board of Nephrology(USA),
MGM group of hospitals & medical college, India
- ▲ Michael Farkouh, MD, FRCP.
University of Toronto, Canada
- ▲ Matthew Weir, MD.
University of Maryland, Baltimore, USA
- ▲ Alan Gradman, MD,
Temple University School of Medicine, PA,USA
- ▲ A. Ramachandran, MD, Ph.D,
MNAMS, FICP, FRCP(Edin)
Diabetes hospital, Chennai, India



INDIA RISK SUMMIT AND BEST OF ASH SYMPOSIUM OCTOBER 11, 2014

SCIENTIFIC PROGRAM - DAY 1

Time	Session	Speaker
9:30 AM - 9.40 AM	Welcome Remarks	<i>Dr. Sanjay Rajagopalan</i>

Controversies and Consensus in Guidelines

Moderator : Dr. Matthew Weir and Dr. G Vijayaraghavan

Time	Session	Speaker
9.40 AM - 10.00 AM	Recommendations for treating hypertension: what are the right goals and purposes?	<i>Dr. Eric Peterson</i>
10.00 AM - 10.20 AM	Clinical Guidelines and Clinical Reasoning-Limitations of Evidence Based Evidence	<i>Dr. Allan Sniderman</i>
10.20 AM -10.40 AM	A Perspective on the 2013 US Guidelines for Hypertension: Where Does the so Called Evidence Based Approach Fall Short?	<i>Dr. Alan Gradman</i>
10.40 AM -11.00 AM	2013 ACC/AHA Cholesterol Treatment Guidelines	<i>Dr. Sanjay Rajagopalan</i>
11.00 AM - 11.20 AM	Coffee Break	
11.20 AM -11.40 AM	Current Guidelines for Treatment of Type II Diabetes: Are We Pushing the Limits of the Evidence Base?	<i>Dr. A. Ramachandran</i>
11.40 AM -12.00 PM	How Does the Clinician Integrate Guidelines into Practice: A Case Based Approach in Hypertension, Lipids and Type II Diabetes	<i>Dr. Matthew Weir Dr. A. Ramachandran Dr. Sanjay Rajagopalan</i>
12.00 PM -12.40 PM	Discussion and Questions and Answers	<i>Dr. Alan Sniderman Dr. Eric Peterson Dr. Matthew Weir Dr. Sanjay Rajagopalan</i>

Mini-symposium on Hypertension

Moderator : Dr. Sanjay Rajagopalan and Dr. Atul Ingale

Time	Session	Speaker
12.40 PM - 1.00 PM	Epidemiology of Hypertension in India: Insights from PURE	<i>Dr. G.Vijayaraghavan</i>
1.00 PM - 1.20 PM	My patient presents with "uncontrolled hypertension": how to rule out pseudo-resistant hypertension causes. A Case Based Discussion	<i>Dr. G.Vijayaraghavan</i>
1.20 PM - 2.10 PM	Lunch	
2.10 PM - 2.30 PM	Approach to the True Resistant Hypertensive and Treatment Approaches	<i>Dr. Matthew Weir,</i>
2.30 PM - 2.50 PM	What Should the Goal Blood Pressure and Ideal Agent(s) be in the Post-Stroke Patient?	<i>Dr. Alan Gradman,</i>
2.50 PM - 3.10 PM	Management of Hypertension in the CKD Patient	<i>Dr. Matthew Weir,</i>
3.10 PM - 3.30 PM	Community Based Intervention for Blood Pressure: What Works and What does not?	<i>Dr. Eric Peterson,</i>
3.30 PM - 4.10 PM	Discussion and Questions and Answers	<i>Dr. Matthew Weir Dr. G Vijayaraghavan Dr. Atul Ingle Dr. Eric Peterson</i>
4.10 PM - 4.30 PM	Coffee Break	

Risk Factor Symposium

Moderator : Dr. Michael Farkouh and Dr. A. Ramachandran

Time	Session	Speaker
4.30 PM - 4.50 PM	What should be our target for LDL lowering therapy and why?	<i>Dr. Allan Sniderman</i>
4.50 PM - 5.10 PM	Newer Treatment Strategies: Mipomersen, Lomitapide and PCSK9	<i>Dr. Sanjay Rajagopalan</i>
5.10 PM - 5.30 PM	Approach and Management of Triglyceride Based Disorders	<i>Dr. Allan Sniderman</i>
5.30 PM - 6.10 PM	Discussion and Questions and Answers	



SPECIAL SYMPOSIUM ON REDUCING RISK IN THE HIGH RISK TYPE II DIABETIC OCTOBER 12, 2014

SCIENTIFIC PROGRAM - DAY 2

Time	Session	Speaker
9:00 AM - 9.10 AM	Introduction	<i>Dr. Sanjay Rajagopalan</i>

Optimizing Management of the Type II Diabetic

Moderators: Dr. Sanjay Rajagopalan and Dr. Atul Ingle

Time	Session	Speaker
9.10 AM - 9.30 AM	Optimizing Anti-Platelet Management in the Type II Diabetic with CAD: Focus on Newer Therapies	<i>Dr. Eric Peterson</i>
9.30 AM - 9.50 AM	Revascularization in Type II Diabetes: Challenges and Evidence from Randomized Clinical Trials	<i>Dr. Michael Farkouh</i>
9.50 AM - 10.10 AM	Glycemic Control for Macrovascular Disease in Type II Diabetes: Evidence and Insights from Recent Trials.	<i>Dr. Sanjay Rajagopalan</i>
10.10 AM - 10.30 AM	Multivessel PCI in the Type II Diabetic: Who Are Appropriate Candidates and Should There be Country Specific Guidelines?	<i>Dr. Michael Farkouh</i>
10.30 AM - 10.50 AM	Coffee Break	
10:50 AM - 11:10 AM	Hypertension Management in High Risk Type II Diabetes with CKD: Insights from Recent Trials with a Focus on Albuminuria. A Case Based Discussion	<i>Dr. Matthew Weir</i>
11.10 AM - 11.30 AM	Statin Induced Diabetes: A Case Based Approach	<i>Dr. Allan Sniderman</i>
11.30 AM - 12.10 PM	Discussion and Questions and Answers	

CME Credit points (India) to participating consultants will be granted*



COURSE INFORMATION:

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

NEED FOR EXPERTISE IN MANAGEMENT OF RISK FACTORS

Hypertension, Type Diabetes and dyslipidemias together pose the greatest risk to the health of Asia and are leading causes of morbidity and mortality due to cardiovascular disease. India is in the midst of an epidemic of obesity, hypertension and Type II diabetes. The emerging tsunami of risk factors in India, leaves no doubts in one's mind that optimal preparation will mandate that every practitioner (GP and specialists) will need to be versed in the optimal management of risk. In particular proficiency and comfort in dealing with hypertension, lipid management and Type II diabetes treatment and incorporation of emerging treatment approaches including new classes of agents will be important. The recent introduction of updated hypertension and lipid guidelines in the United States, have resulted in some interpretative difficulties especially when examined against other guidance documents from societies from Europe, UK and Canada. This conference will focus on understanding optimal approaches for risk factor control and clinical evidence that justify current approaches. In this 1.5 day workshop, attendees will be provided concise clinically relevant information in the form of didactic lectures, in addition to mini-symposia and controversies in a debate format. In addition there is expected to be additional interactions with the audience in a question and answer forum. This symposium will provide expert practitioners the practical science necessary to treat risk factors and will provide the latest information to the attendees.

TARGET AUDIENCE

The target audience will be cardiologists, endocrinologists, internists and family practitioners who direct large clinical practices and/or teach in academic medical institutions. At the end of the conference the participating physicians will be fully capable of taking this new information back to their communities and sharing it with their colleagues.

LEARNING OBJECTIVES

After attending this activity, the participant will demonstrate expertise in the management of the following aspects of hypertension, dyslipidemias and diabetes

Evidence for blood pressure goals and new guidance from guidelines including how low to go and with what to treat

Understanding newer treatment paradigms in hypertension and the evolving role of beta blockade, renin blockade, dual RAS blockade etc.

- New technologies for treatment of hypertension and treatment of resistance hypertension and current role



Emerging themes of measuring risk in the asymptomatic patients

Newer and emerging therapies for treating LDL-C and triglycerides including new guidance on targets

Targeting risk in the Type II Diabetic with the role of DPP-4 inhibitors and GLP-1 agonists in reducing risk in diabetes

The role of adjunctive pharmacotherapies in the diabetic including anti-platelet agents

ACCREDITATION

This meeting is being conducted under the auspices of the American Society of Hypertension (ASH). On completion, a certificate of participation will be provided.

DISCLOSURE POLICY

FACULTY DISCLOSURE POLICY

The ASH hopes to ensure balance, independence, objectivity and scientific rigor in the 2014, India Risk Summit and Best of American Society of Hypertension (ASH) Update in Hyderabad India. The content and format of this course and its related materials are developed to promote improvements in the quality of healthcare and not to promote commercial interests.

All faculty members participating in sponsoring programs are expected to disclose to the audience any potential, apparent, or real conflict of interest related to their contribution to this activity. Recommendations for medical practice must be based on evidence that is accepted within the profession as adequately justified. Investigational approaches should be identified as such. Furthermore, all scientific research to which faculty members refer, report, or use in support or justification of patient care recommendations must conform to the generally accepted standards of biomedical research. Whenever possible, presenters, authors and planners should reference the best available evidence and describe the level of evidence.

FACULTY DISCLOSURES

In meeting the requirement of full disclosure, the presenters have indicated that they have a relationship which they do not consider a real or apparent conflict of interest in the context of their presentation, nor do they believe that it will influence their presentation.

